D. E. Shaw & Co. Inc. Purchases 91,529 Shares of Accuray Incorporated (NASDAQ:ARAY)

D. E. Shaw & Co. Inc. lifted its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,793,391 shares of the medical equipment provider’s stock after acquiring an additional 91,529 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Accuray were worth $3,551,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ARAY. Ameriprise Financial Inc. bought a new stake in shares of Accuray during the 4th quarter worth approximately $35,000. Prudential Financial Inc. bought a new stake in shares of Accuray during the 4th quarter worth approximately $43,000. Susquehanna Fundamental Investments LLC bought a new position in Accuray in the 4th quarter valued at approximately $66,000. Gabelli Funds LLC lifted its stake in Accuray by 12.5% in the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 5,000 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Accuray by 37.4% in the 4th quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 12,259 shares during the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Price Performance

Shares of NASDAQ:ARAY opened at $1.62 on Monday. The company has a market cap of $166.88 million, a price-to-earnings ratio of -32.40 and a beta of 1.30. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. The firm has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.91. Accuray Incorporated has a one year low of $1.28 and a one year high of $2.95.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04. The business had revenue of $113.24 million during the quarter, compared to the consensus estimate of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Research analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Accuray from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.